Basel, Switzerland, 25 April 2024 – Risklick, a spin-off from the University of Bern, launched its latest product, Protocol AI. The first of its kind, Protocol AI uses artificial intelligence to enable drafting of clinical trial protocols within minutes to accelerate the development of clinical trials, reduce costs and increase safety standards. Currently developing a new protocol demands an average of 12 months of intensive work mining the vast number of diverse clinical trial registries, where the slightest error can lead to disastrous consequences.
AI-based software gives patients faster access to therapies
To address the challenges, the spin-off from the University of Bern Risklick has developed Protocol AI. “We have created a pioneering solution that reduces the development time and costs of clinical trials by up to 35%, making it easier for patients to access therapies. Our innovative technology has the potential to improve the lives of millions of patients worldwide,” says Poorya Amini, co-founder and CEO of Risklick.
Protocol AI uses artificial intelligence to analyze existing clinical data, optimizing their selection and integration through Natural Language Processing (NLP). By extension, Protocol AI facilitates evidence-based decision making and automatic drafting of clinical trial protocols within minutes, utilizing cutting-edge technology based on Large Language Models (LLM) and Machine Learning (ML).
Protocol AI allows experts to drastically reduce the development time of protocols while ensuring the quality, as well as increasing the chances of success of the clinical trial. The AI based tool accelerates and simplifies the development of new treatments, paving the way for medical innovation.
With Debiopharm, a leading biotechnology company in French-speaking Switzerland, and Integrated Scientific Services, ISS AG, a Swiss clinical research company with expertise in medical devices, digital medicine and IVD, Risklick has already attracted major players from both the pharmaceutical and medical device industries as partners. They see Protocol AI as the ideal solution to the challenges of developing new therapies.
“Our investment in Risklick is a strategic enhancement to our R&D, Clinical Operations, and Regulatory Affairs workflows. Through Protocol AI, we not only accelerate the delivery of innovative treatments but also ensure more efficient trial designs and robust compliance, addressing internal challenges with cutting-edge solutions that benefit our collaborators and patients globally,” says Cédric Odje, Investment Associate at Debiopharm.
“Our interest in partnering with Risklick and their product Protocol AI is to gain access to a unique solution that improves quality by systematically and profoundly bringing together all relevant sources of information and automatically track changes throughout the protocol. Protocol AI will improve the design of clinical investigations and thus support the generation of accurate therapeutic data related to medical devices, digital medicines and IVDs,” adds Michel Weber, Division Leader Clinical Services at ISS AG.
Protocol AI’s technological innovation is also valued by Advanced Clinical, a clinical research organization with decades of experience. Paul Miller, Vice President Commercial Strategy at Advanced Clinical: “Protocol AI offers a unique solution in minimizing AI distortions through precise queries and extracting validated data from diverse registries. This transformative capability can revolutionize clinical trial design and enhance industry access to accurate therapeutic data.”
